Form 10-K BRAINSTORM CELL THERAPEU For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Brainstorm Cell Therapeutics (BCLI) Tops Q4 EPS by 8c; Net R&D Expenses Halved
March 10, 2016 7:55 AM ESTBrainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q4 EPS of ($0.07), $0.08 better than the analyst estimate of ($0.15).
Net R&D expenses for the fourth quarter of 2015 were $0.8 million, compared with $1.6 million for the fourth quarter of 2014.
For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.
... More